Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 147 от 154

Активно (без набиране) Фаза 1

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

Follicular Lymphoma

Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR trial

Начало: 07.09.2017 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia Dr. Eliza Hawkes NCT03245021

Активно (без набиране) Фаза 1

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Urothelial Carcinoma Renal Cell Carcinoma Non-Small Cell Lung Cancer Castration-resistant Prostate Cancer +10

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Начало: 05.09.2017 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +6 Exelixis NCT03170960

Активно (без набиране)

PRecISion Medicine for Children With Cancer

Childhood Cancer Childhood Solid Tumor Childhood Brain Tumor Childhood Leukemia +2

This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.

Начало: 05.09.2017 Край: 01.12.2032 Възраст: до 21 г.

Australia Sydney Children's Hospitals Network NCT03336931

Активно (без набиране)

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Early Stage Breast Carcinoma

This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

Начало: 21.08.2017 Край: 01.04.2028 Възраст: от 50 г. Лечение

Argentina, Australia, Chile +6 Breast Cancer Trials, Australia and New Zealand NCT02889874

Активно (без набиране) Фаза 1

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Solid Tumors

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.

Начало: 14.08.2017 Край: 21.11.2027 Възраст: от 18 г. Лечение

Australia, Japan, United Kingdom +1 ModernaTX, Inc. NCT03313778

Активно (без набиране) Фаза 3

A Study to Compare the Long-term Outcomes After Two Different Anaesthetics

Anesthesia Neurotoxicity Child Development

There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

Начало: 10.08.2017 Край: 01.06.2026 Възраст: до 2 г. Лечение

Australia, Italy, Spain +1 Murdoch Childrens Research Institute NCT03089905

Активно (без набиране) Фаза 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.

Начало: 08.08.2017 Край: 30.09.2027 Възраст: 1–21 г. Лечение

Australia, Belgium, Canada +14 Children's Oncology Group NCT03007147

Активно (без набиране) Фаза 2

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Advanced Malignant Solid Neoplasm Ann Arbor Stage III Non-Hodgkin Lymphoma Ann Arbor Stage IV Non-Hodgkin Lymphoma Histiocytic Sarcoma +41

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Начало: 31.07.2017 Край: 06.01.2027 Възраст: 12–21 г. Скрининг

Australia, Canada, Puerto Rico +1 National Cancer Institute (NCI) NCT03155620

Активно (без набиране) Фаза 2

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Waldenstrom Macroglobulinemia Multiple Myeloma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma +5

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Начало: 26.07.2017 Край: 22.12.2027 Възраст: от 18 г. Лечение

Australia, Brazil, Czechia +8 Cellectar Biosciences, Inc. NCT02952508

Активно (без набиране)

The Chocolate Touch Study

Peripheral Artery Disease (PAD) Ischemia Intermittent Claudication

The Chocolate Touch study is a randomized, multi-center, prospective, adaptive study, designed to show sufficient safety and effectiveness of the Chocolate Touch™ for use in superficial femoral or popliteal arteries with the intention of obtaining regulatory approval to market this device in the United States

Начало: 26.07.2017 Край: 01.12.2026 Възраст: от 18 г. Лечение

Austria, Germany, New Zealand +1 TriReme Medical, LLC NCT02924857

Активно (без набиране) Фаза 3

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Начало: 23.07.2017 Край: 16.01.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +15 Bristol-Myers Squibb NCT03141177

Активно (без набиране) Ранна Фаза 1

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

Lymphomas Non-Hodgkin's B-Cell

To evaluate the feasibility of adding induction and maintenance Avelumab to the standard combination of R-CHOP in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)

Начало: 21.07.2017 Край: 01.07.2025 Възраст: от 18 г. Лечение

Australia Austin Health NCT03244176

Активно (без набиране) Фаза 2

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

Soft Tissue Sarcoma of the Extremity

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

Начало: 19.07.2017 Край: 01.09.2028 Възраст: от 12 г. Лечение

Australia, Canada, Italy +1 Sarcoma Alliance for Research through Collaboration NCT03092323

Активно (без набиране) Фаза 3

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Newly Diagnosed Acute Myeloid Leukemia (AML) Untreated AML AML Arising From Myelodysplastic Syndrome (MDS) Leukemia, Myeloid, Acute

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult participants with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is event-free survival (EFS). The key secondary efficacy endpoints are overall survival (OS), rate of complete remission (CR), rate of CR and complete remission with partial hematologic recovery (CRh), and overall response rate (ORR). Participants eligible for study treatment based on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched placebo, both administered in combination with subcutaneous (SC) or intravenous (IV) azacitidine. An estimated 200 participants will take part in the study.

Начало: 26.06.2017 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +16 Institut de Recherches Internationales Servier NCT03173248

Активно (без набиране) Фаза 3

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

HER-2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

Начало: 21.06.2017 Край: 31.07.2026 Възраст: от 18 г. Лечение

Australia, France, Germany +5 Alliance Foundation Trials, LLC. NCT02947685

Активно (без набиране) Фаза 3

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3

Начало: 08.06.2017 Край: 13.08.2027 Възраст: 2–65 г. Лечение

Australia, Belgium, Canada +15 Novartis Pharmaceuticals NCT02962414

Активно (без набиране)

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Recurrent Neuroblastoma Stage 2A Neuroblastoma Stage 2B Neuroblastoma Stage 3 Neuroblastoma +2

This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.

Начало: 05.06.2017 Край: 30.09.2026 Възраст: 5–50 г.

Australia, Canada, New Zealand +1 Children's Oncology Group NCT03057626

Активно (без набиране)

REDUCE LAP-HF TRIAL II

Heart Failure

Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.

Начало: 01.06.2017 Край: 01.09.2026 Възраст: от 40 г. Лечение

Australia, Belgium, Canada +10 Corvia Medical NCT03088033

Активно (без набиране)

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

Revision Total Knee Arthroplasty

Five-year, Prospective, multi-center, non-randomized, non-controlled study of the ATTUNE® Revision total knee prostheses, utilizing the fixed bearing (FB) and rotating platform (RP) tibial component with the posterior stabilizing (PS) femoral component in revision total knee arthroplasty.

Начало: 30.05.2017 Край: 31.03.2029 Възраст: 22–80 г. Лечение

Australia, Belgium, Canada +9 DePuy Orthopaedics NCT03153475

Активно (без набиране) Фаза 4

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell Lymphoma, Non-Hodgkin Leukemia, B-cell Graft Vs Host Disease +1

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Начало: 22.05.2017 Край: 10.05.2027 Възраст: от 18 г. Лечение

Australia, Canada, Czechia +14 Pharmacyclics Switzerland GmbH NCT03229200

1 … 145 146 147 148 149 … 154